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a  b  s  t  r  a  c  t
Dogs  with  lymphoma  are  established  as  good  model  for human  non-Hodgkin  lymphoma  studies.  Canine
cell lines  derived  from  lymphomas  may  be valuable  tools  for testing  new  therapeutic  drugs.  In this  context,
we  established  a canine  T-cell  line,  PER-VAS,  from  a primary  aggressive  T-cell  lymphoma  with  large
granular  morphology.  Flow  cytometric  analysis  revealed  a stable  immunophenotype:  PER-VAS  cells  were
positively  labelled  for CD5,  CD45,  MHC  II and  TLR3,  and  were  negative  for  CD3,  CD4  and  CD8  expression.
Although  unstable  along  the  culture  process,  IL-17  and  MMP12  proteins  were  detectable  as late  as  at




maintained  the  expression  of  IL-17,  CD3, CD56,  IFN  and  TNF  mRNAs  as  shown  by RT-PCR  analysis.
Stable  rearrangement  of  the  TCR  gene  has  been  evidenced  by  PCR.  PER-VAS  cells  have  a high  proliferation
index  with  a doubling  time  of  16.5 h and were  tumorigenic  in  Nude  mice.  Compared  to  the  canine  cell
lines  already  reported,  PER-VAS  cells display  an original  expression  pattern,  close  to NKT  cells,  which
makes  them  valuable  tools  for in vitro  comparative  research  on  lymphomas.
©  2015  The  Authors.  Published  by  Elsevier  GmbH.  This  is  an  open  access  article  under  the  CC. Introduction
Non Hodgkin lymphomas represent the most frequent canine
ematopoietic tumour with an incidence of 15–30/100 000 sim-
lar to human (Marconato et al., 2013; Vail and MacEwen, 2000).
oreover, dogs develop spontaneous lymphomas resembling the
uman tumour regarding the type, grade, site of involvement
nd clinical features. The canine NHL classiﬁcation followed the
uman classiﬁcation by grouping lymphomas according to their
ytological characteristics (updated Kiel classiﬁcation (Lennert,
991)) and more recently based on the revised European–American
Harris et al., 1994) and World Health Organization (WHO)
lassiﬁcation (Jaffe, 2001; Pileri et al., 1998; Swerdlow, 2008)
aking into account phenotypic, genetic and molecular features
Fournel-Fleury et al., 1997, 2002; Ponce et al., 2010; Turinelli
t al., 2005; Valli et al., 2011). Importantly, dogs and humans
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sharing the same environment, the cartography of human and
canine lymphomas related to outdoor carcinogens contributes
to the evaluation of environmental risk factors (Pastor et al.,
2009).
In human, peripheral T-cell lymphomas (PTCL) represent a
group of heterogeneous lymphomas characterized by clonal expan-
sion of T or NK cells with generally poorer prognosis than B-cell
lymphomas. Standard therapeutic regimens resulted in insufﬁcient
patient outcomes with a rapid relapse and poor 5-years over-
all survival rates (Coifﬁer et al., 2014). Since PTCL account for
approximatively 10–15% of all non-Hodgkin lymphomas in West-
ern countries, therapeutic strategy of large clinical trials could not
be conducted as for B-cell lymphomas counterparts (Gooptu et al.,
2015; Jain et al., 2015). Therefore, new therapeutic approaches are
required, especially for highly aggressive clinical forms showing
multidrug resistance like extranodal NK-T cell lymphomas (Gill
et al., 2010). Unfortunately, the lack of valuable preclinical model
as well as the difﬁculties to derive cell lines phenotypically close to
the primary tumors restricted the opportunities to test potentially
new reagents towards PTCL.
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In dogs, PTCL also represent a heterogeneous group with vari-
us prognoses (Fournel-Fleury et al., 2002; McDonough and Moore,
000). Among them, Large Granular Lymphomas (close to human
xtranodal NK/T-cell lymphomas) displayed a very high aggres-
ive clinical course, often associated with hemophagocytic and
acrophages activation syndromes and very poor overall survival
ates (Turinelli et al., 2005). Therefore, the opportunity to develop a
reclinical spontaneous canine model or to obtain canine NK/T-cell
ine to assess novel therapeutic approaches for such lymphomas
onstitutes a major challenge.
To date, twelve still available canine cell lines have been
escribed and characterized according to their morphology,
mmunophenotype, pattern of TCR genes status and ability to
nduce tumours in mice (Kisseberth et al., 2007; Momoi  et al., 1997;
akaichi et al., 1996; Rutgen et al., 2010; Steplewski et al., 1987;
uter et al., 2005; Umeki et al., 2013; Yamazaki et al., 2008). Impor-
antly, cell phenotype may  change either from the primary material
o the establishment of the cell line (Rutgen et al., 2010) or during
n vitro maintenance (Umeki et al., 2013), leading to differences in
he pattern of expression of speciﬁc markers. In this context, long-
erm study of ex-vivo derived cells is crucial to adequately establish
heir phenotype.
In the present study, we followed the morphology as well as the
xpression of the CD3, CD56, IL-17, TNF and INF markers in the
ER-VAS T-cell line, derived from an aggressive large granular T-
ell lymphoma, along 325 in vitro passages (over four years). We
escribed a new lymphoma-derived cell line expressing markers
imilar to the tumour it originated from.
. Materials and methods
.1. Case report
A seven year old male Labrador was initially diagnosed with
eishmaniasis (assessed with serological and PCR tests), and was
resented to the veterinary hospital for severe dyspnea and
sthenia. The dog showed moderate regenerative normochromic
ormocytic anemia, with the following hemogram values: red
ells: 3.53 tera/L; hemoglobin: 7.8 g/dL; hematocrit: 22.3%; VGM:
3 fL; CCMH: 34.8 g/dL; TCMH: 22 pg; reticulocytes: 0.5%. No
bnormal lymphoid cells were present on the peripheral blood
mear. The ultrasonic scan conﬁrmed a pleural and pericardial
xtravasation with cardial tamponade related to the main clinical
igns (severe dyspnea and asthenia) and the absence of abnor-
al  neoplastic mass. The abdominal ultrasonic examination gave
o additional information. Cytological examination showed that
ericardial effusion was mainly composed of tumoral cells with lab-
ratory values indicating cell count: 29.5 × 103/mm3 and protein:
.4 g/dL. Pleural effusion displayed a mix  of mesothelial, histio-
ytic, lymphocytic, neutrophilic and rare tumoral cells, with cell
ount: 2.67 × 103/mm3 and protein: 5.8 g/dL. Axillary and popliteal
ymph nodes were slightly enlarged at the ﬁrst clinical examina-
ion, but ﬁne needle aspiration of these superﬁcial lymph nodes
howed no signs of tumoral cells. An aggressive T-cell lymphoma
ith large granular cell morphology was diagnosed on cytologi-
al examination of pericardial and pleural effusion aspirations. The
isease progressed rapidly towards death before any chemother-
py. No histopathological information was available because the
utopsy was unauthorized by the dog’s owner.
.2. Establishment of PER-VAS lymphoma cell lineCells from the pericardial effusion were cultured at 106 cells/ml
nd 5 × 105 cells/ml in complete RPMI medium (RPMI 1640
edium supplemented with 20% fetal calf serum, 2 mM l-obiology 221 (2016) 12–22 13
glutamine, 1% penicillin/streptomycin) in 75 cm2 ﬂasks at 37◦C in
humidiﬁed atmosphere with 5% CO2. Passages were conducted 3
times a week by replacing half of the culture with fresh complete
RPMI medium. Primary effusion consisted of a mixed cell pop-
ulation including lymphocytes, histiocytes, mesothelial cells and
atypical lymphocytes with large acidophilic cytoplasmic granules.
After 3 weeks of culture with 3 passages a week, cells started to
grow in suspension forming ﬂoating cell clusters. The cells were
maintained in continuous culture during 9 months with high pro-
liferative growth, and were then stored in liquid nitrogen at a
concentration of 10 × 106 cells/ml in 90% FCS, 10% DMSO at passage
142. In a second period, PER-VAS cell line was thawed 4 months
later for culturing from passages 143 to 199 during 7 months, and
then was frozen at passage 199. In a third period, the cell line was
thawed 2 months later from passages 200 to 280 during 8 months
before freezing. The fourth period began one year and a half later
from passages 281 to 325 during 5 months and immunophenotype
was assessed. Splitting was conducted 15 times per month during
the ﬁrst cycle by replacing half of the culture with fresh complete
RPMI medium. SVF was maintained at 20% in the medium up to pas-
sage 150 and then decreased to 10% for the following cycles. From
the second cycle and further, 5 × 105 cells were seeded in 25 cm2
ﬂasks and were subcultured 8–10 times per month by replacing
at least three quarters of the culture with fresh complete RPMI
medium. Finally, PER-VAS cell line was  cultured along 325 passages
over four years through 4 freezing/thawing cycles.
PER-VAS cells were cloned at passage 200 by seeding at a den-
sity of ≤1 cell per well in 96-well ﬂats bottom culture plates (Nunc).
Twenty four out of the 32 clones obtained were expanded and
analysed for antigen receptor rearrangements and phenotype.
For doubling time calculation, cells were seeded in triplicate at
2 × 104 cells/well in 96-well plate; viable cells were counted every
24 h for 3 days using trypan blue dye exclusion. The logarithmic
least squares ﬁtting technique was used for the calculation (Roth,
2006).
2.3. Primary cells and cell lines used as controls
A20 murine B cell lymphoma and Jurkat human T-cell leukemia
cell lines were obtained from the CelluloNet facility (SFR Bio-
Sciences Gerland-Lyon Sud, UMS3444/US8). They were used as
positive controls for western-blot analysis of Per-Vas cells for
IL17 and MMP12 expression, respectively and in comparison with
canine and human PBMC. Canine PBMC were isolated form healthy
adult beagle dogs (Claude Bourgelat Institut of the VetAgro Sup vet-
erinary campus, Lyon, France) in accordance with the institutional
guidelines. Human PBMC were obtained from healthy donors under
informed consent (Etablissements Franc¸ ais du Sang, Lyon, France).
RT-PCR analysis of PER-VAS cells were done in comparison with
canine leukemia T-cells (CD3+/CD5+/CD45+/CD4−/CD8−/CD21−).
Lymphoid hyperplasia T- and B- cells from ﬁne needle aspiration
of lymph nodes were obtained from dogs sampled at Vetagro Sup
Veterinary campus and were used as positive control for clonality
assessment (PARR assay).
2.4. Phenotype analysis
PER-VAS cells were analyzed by ﬂow cytometry from pas-
sages 25 to 325. Immunocytochemistry was performed on primary
pericardial effusion and on PER-VAS cells at passage 240 using
cytospin smears. Cells were labelled with monoclonal antibod-
ies listed in Table 1. For ﬂow cytometry analysis, 1– 5 × 105 cells
were incubated with mAb  or isotype matched irrelevant Igs for
30 min  at 4◦C. For indirect staining, after a PBS washing, FITC-
labelled anti-mouse secondary antibody was  incubated for 30 min
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Table 1
Antibodies used in this study.
Speciﬁcity Clone Isotype Conjugation Application used Source References for cross reactivity
Human CD1a NA1/34-HLK mIgG2a –a FC Serotec, Oxford, UK Galkowska et al. (1996)
Canine CD3 CA17.2A12 mIgG1 FITC FC Serotec, Oxford, UK –
Human CD3 CD3-12 rIgG1 –a FC, ICC Serotec, Oxford, UK Jones et al. (1993)
Human CD3 polyclonal rabbit – ICC Dako, Glostrup, Denmark Jones et al. (1993)
Canine CD4 YKIX302.9 rIgG2a FITC FC, ICC Serotec, Oxford, UK –
Canine  CD5 YKIX322.3 rIgG2a FITC FC, ICC Serotec, Oxford, UK –
Canine  CD8 YCATE55.9 rIgG1 FITC FC, ICC Serotec, Oxford, UK –
Canine  CD11c CA11.6A1 mIgG1 –a FC Serotec, Oxford, UK –
Human CD14 TÜK4 mIgG2a –a FC Dako, Glostrup, Denmark Drexler (2001)
Canine CD21 CA2.1D6 mIgG1 PE FC Serotec, Oxford, UK –
Canine  CD45 YKIX716.13 rIgG2b FITC FC Serotec, Oxford, UK –
Canine  MHC  II YKIX334.2 rIgG2a FITC FC Serotec, Oxford, UK –
Canine  TCR CA15.8G7 mIgG1 – ICC P.F. Moore, UC Davis –
Canine  TCR CA20.8H1 mIgG2a – ICC P.F. Moore, UC Davis –
Human TLR3 722E2 mIgM –a FC, WB  Gift from Dendritics, Lyon, France Bonnefont-Rebeix et al. (2007)
Human IL-17 412H6 mIgG1 –a FC, WB  Gift from Dendritics, Lyon, France This study
Human MMP12 703D10 mIgG1 –a FC, WB  Gift from Dendritics, Lyon, France This study
Anti-mouse Ig – Goat Ig FITC FC Dako, Glostrup, Denmark –




































vbbreviations: m = mouse; rat; FC = ﬂow cytometry; ICC = immunocytochemistry; W
a Required anti-mouse Ig - FITC-labelled secondary antibody for ﬂow cytometry.
t 4◦C. Intracellular staining for CD3 (dilution 1:100), TLR3, IL-17
nd MMP12 (16 g/ml) was performed after permeabilization with
.3% saponin (SIGMA) in PBS. Cells were analyzed on a BD Accuri
ow cytometer (BD Biosciences).
Immunocytochemistry was performed on cytospin smears
sing the UltraTek HRP Anti-Polyvalent kit (ScyTek Laborato-
ies) with Vector® NovaREDTM (Vector Laboratories) as substrate,
ollowing the manufacturer’s instructions, with hematoxylin coun-
erstaining. Negative control was performed without the primary
Ab. TCR and TCR staining were kindly performed by Pr Peter
. Moore, U.C. Davis, California, USA.
.5. Western Blot
Canine and human PBMC, A20, Jurkat and PER-VAS (at passage
80) cells were lysed as previously described (Bonnefont-Rebeix
t al., 2007). Cell lysates were denatured at 95◦C for 5 min  in
he presence of 2% -mercaptoethanol and 2% SDS. Recombi-
ant human MMP12 produced in COP5 murine cells (rhuMMP12,
ift from Dendritics, Lyon, France) was used as positive control
or MMP12 detection. Fifteen g of proteins were separated on
2 or 15% SDS-PAGE and blotted onto nitrocellulose membranes.
embranes were blocked with “Protein-Free T20 Blocking Buffer”
Thermo Scientiﬁc Pierce) at room temperature for 10 min. before
ncubation for 1 h at room temperature and overnight at 4◦C
ith anti-IL-17A mAb  (9 g/ml) and anti-MMP12 mAb (15 g/ml)
Dendritics, France). Blots were developed as previously described
Bonnefont-Rebeix et al., 2007).
.6. Polymerase chain reaction for antigen receptor
earrangements (PARR)
For clonality assessment, both immunoglobulin and T-cell
eceptor  (TCR) genes rearrangements were investigated using
ARR as previously described (Burnett et al., 2003). Total genomic
NA was extracted from 5 × 106 frozen primary effusion cells and
ER-VAS cells at passages 145, 205 and 325 using the “NucleoSpin®
issue kit” (Macherey Nagel). Cells from lymphoid T- and B-
yperplasia with polyclonal receptor rearrangement were included
n all assays as controls. PCR reactions were carried out at 95◦C for
 min, followed by 40 cycles at 95◦C for 45 s, 55◦C for 45 s and 72◦C
or 45 s. PCR products were separated onto 2.5% agarose gel and
isualized after staining with GelRed (Thermo scientiﬁc).estern blot analysis.
2.7. mRNA expression
Total RNA was extracted from PER-VAS cells at passages 280
and 325 and from canine leukemia CD3+ T-cell using the “Ambion®
PureLink® RNA Mini Kit” (Life technologies). After DNase treat-
ment (“Ambion® TURBO DNA-free DNase Treatment and Removal
Reagents”), 100 ng of total RNA were reverse-transcribed using the
“iScriptTMcDNA Synthesis Kit” (Bio-Rad). RT-negative controls have
been performed to conﬁrm the absence of contaminating DNA.
PCR reactions were performed in 20 l with 10–200 ng of cDNA
using the “KapaTM Taq DNA Polymerase kit” (Kapa Biosystems).
The ampliﬁcation was performed at 95◦C for 3 min, followed by 40
cycles of 95◦C for 20 s, 60◦C (except 63◦C for IL17) for 20 s and 72◦C
for 20 s using dog-speciﬁc primers (0,2 M)  for CD3, CD56, INF,
TNF, IL-17, MMP12, and ACTB as housekeeping gene (Table 2). PCR
products were size-fractionated on a 2% agarose gel.
2.7. Tumorigenicity assay
Xenografted tumor cell assays were conducted in Cancer
Research Center, Toulouse, France, in accordance with the Ani-
mal  Care and Use Committee (approval number 06 563DG-04).
Two adult (7 weeks old) athymic nude mice (RjOrl:NMRI-
Foxn1nu/Foxn1nu) were inoculated subcutaneously in the right
side with 107 PER-VAS cells (passage 60) in 0.25 ml PBS per mouse.
Mice were observed weekly for tumour growth. Euthanasia was
conducted 11 weeks after inoculation. Tumor mass was  excised
from the inoculation site and ﬁxed in 10% formalin and embed-
ded in parafﬁn. For tissue morphology, glass slides sections were
prepared and stained with hematoxylin and eosin (HE).
3. Results
3.1. Characteristics of the primary effusion cells and
establishment of PER-VAS cell line
The primary malignant pericardial effusion of the 7 year-
old male Labrador consisted of a mixture of median-sized and
large lymphoma cells with nucleus twice larger than an ery-
throcyte (Fig. 1A) in a hemorrhagic background. These cells
displayed a high nuclear/cytoplasmic ratio, irregularly folded
nuclei, irregular coarse chromatin, poorly visible pale nucleoli, and
a basophilic cytoplasm containing numerous microvacuoles and
some azurophilic granules. Expression of CD3, CD4, CD8, CD79a,
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Table  2
Oligonucleotide primers used for RT-PCR of PER-VAS.
Target gene Accession number Primer Nucleotide sequence (5′-3′)
CD3 XM 536556 FORREV GAACAATCCGACAAAGCACCT
AGTGGCGATTATGTCAGCGA
CD56  AY860627 FORREV TTGTCCCCAGCCAAGGAG
TAGATGGTGAGCGTGGAGGAAGA
INF  NM 001003174 FORREV GGCTGTAACTGTCAGGCCAT
ACGAAAAGAGACCCACTC
TNF  NM 001003244 FORREV GCCTGCTGCACTTTGGAGT
GTTGGCCAGGAGGGCATT
IL-17  NM 001165878 FORREV CTGAGCCTGGTGGCTATCAT
GGGCCTTCTGGAGTTCGTATT
ACTB  NM 001009784 FORREV CCAACCGTGAGAAGATGACC
CCAGAGGCGTACAGGGACAG
Fig. 1. Comparative features of the primary malignant pericardic effusion and the established PER-VAS cell line.
(A).  The primary malignant pericardic effusion displayed an important contingent of medium-sized and large lymphoma cells with a basophilic cytoplasm containing
numerous clear vacuoles (*) and azurophilic granules (→) in a hemorrhagic background. (B). PER-VAS cells established from the primary malignant pericardic effusion
showed large cells with a high nuclear to cytoplasmic ratio very similar to the primary effusion cells, and a deep basophilic cytoplasm containing rare azurophilic granules
(→).  Staining with May-Grünwald-Giemsa stain, original magniﬁcation ×100.
Fig. 2. Immunocytochemistry on primary effusion cells (A, B) and PER-VAS cell line (C, D) smears using monoclonal (A, C) and polyclonal (B, D) anti-CD3.
(A)  Primary effusion cells showing a positive staining for normal lymphocyte (*) whereas atypical medium-sized and large lymphocytes (→) are negative (through background)
using  CD3 mAb. (B) Positive staining of primary malignant effusion cells using polyclonal rabbit anti-human T-cell CD3. (C) Negative staining of PER-VAS cell line at passage
325  using CD3 mAb. (D) Positive staining of PER-VAS cell line at passage 325 using polyclonal anti-CD3.
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Fig. 3. PCR for TCR gene rearrangement.
Stable monoclonal TCR rearrangement of the primary lymphoma effusion cells, the
established PER-VAS cell line at passages 145, 205 and 325, and 10 clones out of the
































ps well as of TCR and TCR were undetectable by immunocy-
ochemistry analysis of lymphoma cells. Interestingly, a positive
taining was obtained only when a polyclonal anti-human T-cell
D3, also targeting an intra-cytoplasmic peptide epitope on the
-chain of the CD3 is used (Fig. 2A and B).
PER-VAS cell line derived from the primary malignant peri-
ardial effusion was cultured over 4 years during four periods
passages 1–142; passages 143–199, passages 200–280 and pas-
ages 281–325), with periodic freezing/thawing. PER-VAS cells
howed a doubling time of 16.5 h and grew in suspension with
umerous clusters of large round to ovoid non-adherent cells
orphologically very similar to the primary effusion cells. May-
rünwald-Giemsa staining revealed a high nuclear to cytoplasmic
atio, a basophilic cytoplasm and a few azurophilic granules
Fig. 1B). Using immunocytochemistry on cytospin smears at pas-
age 325, CD3 staining was found negative using the monoclonal
ntibody (Fig. 2C), but positive, as were the cells from the pri-
ary effusion, when using the polyclonal anti-intra-cytoplasmic
Fig. 2D). TCR and TCR were undetectable both in primary
ffusion cells and in PER-VAS cell line at passage 280.
PARR analysis revealed a clonal TCR gene rearrangement in pri-
ary effusion cells and in PER-VAS cells at passages 145, 205 and
25 (Fig. 3). The same TCR clonal rearrangement was found in
4 independent clones derived form PER-VAS cell-line. Sequenc-
ng analysis conducted on primary effusion cells and a randomly
hosen PER-VAS cells clone conﬁrmed the identical clonal rear-
angement of the TCR gene.
ig. 4. PER-VAS cell-growth in mice.
A) Histological section shows the location of tumor cells forming dense areas (*) within 
uscle  (m)  at the site of injection (subcutaneously). (B) Tumor consists of large cells with n
rominent multiple nucleoli (*), and frequent mitotic ﬁgures (→). HE stain.obiology 221 (2016) 12–22
3.2. Tumor cell growth in mice
PER-VAS cells (passage 60) subcutaneously injected in two
nude mice produced expanding tumors macroscopically detected
5 weeks after inoculation. Only one mouse survived and was
euthanized 11 weeks after inoculation with tumor mass reach-
ing 1 × 1.5 × 0.8 cm at the injection site. HE stained sections of
tumor mass showed the location of tumor cells forming dense
areas within murine loose subcutaneous connective tissue (Fig. 4A).
Microscopic examination (Fig. 4B) revealed that tumor areas con-
sisted exclusively of large cells presenting blastic aspect: narrow
hyperacidophilic cytoplasmic rim, large nucleus containing coarse
chromatin and prominent multiple nucleoli. Mitotic ﬁgures were
frequent. This morphology was in accordance with a canine high-
grade large-cell lymphoma. A lymphoproliferative reaction to the
inoculation would have shown a population of small blastic cells
with decondensed chromatin, but such small reactive lymphocytes
were not observed, suggesting that tumor derived from the injected
PER-VAS cells.
3.3. Immunophenotype of PER-VAS cell-line
The immunophenotype of PER-VAS cells was investigated at
passages 25, 50, 145, 150, 205, 220, 260, 280 and 325 (Table 3).
Cells showed stable surface expression of CD5, CD45, MHCII, stable
cytoplasmic expression of TLR3, and were negative for the expres-
sion of CD4, CD8, CD21, CD14 (Fig. 5A). PER-VAS cells were negative
for CD1a and CD11c at 2 passages 25, 220 and 260. CD3 staining
showed 60% of weakly positive cells at passage 25, remaining sta-
ble by passage 50, and then rapidly decreasing from only 14% by
passage 145 (ﬁve days after thawing) to no positive cells at passage
150 two  weeks later (Fig. 5B); the loss of CD3 staining was con-
ﬁrmed in all further ﬂow cytometry analysis. Surface expression
of CD3 was  ﬁrst investigated at passage 205 and showed constant
negative result along further passages (Table 3).
Expression of IL-17 and MMP12 analysed by ﬂow cytometry was
unstable over time. Initially weak at passage 50, 16 weeks after cell
derivation, expression of IL-17 and MMP12 were respectively unde-
tectable and weak by passage 220, and then positive at passages
260, 280 and 325 (data not shown). IL-17 and MMP12 expression
detected by ﬂow cytometry at passage 280 (Fig. 6A and C) was con-
ﬁrmed by Western blot analysis (Fig. 6B and D). RT-PCR analysis
conﬁrmed the presence of IL-17 mRNA at passages 280 and 325 in
comparison with canine leukemia CD3+ T cells, as well as CD3,
CD56, IFN and TNF mRNA (Fig. 7).terization of PER-VAS cell line, a novel canine lymphoma cell line.
murine loose subcutaneous connective tissue (→) and inﬁltrating skeletal striated
arrow hyperacidophilic cytoplasmic rim, large nucleus containing coarse chromatin,
C. Bonnefont-Rebeix et al. / Immunobiology 221 (2016) 12–22 17
Fig. 5. Flow cytometry analysis of PER-VAS cell line.
(A) Stable expression of CD5, TLR3 and MHCII, and constant negativity for CD21, CD4, CD8 and CD45 at passage 150, representative of 9 analyses along 325 passages. Dot
plot  depicting forward/side scatter (FSC/SSC) is shown to illustrate population gating. (B) Decrease of CD3 staining over passages 50, 145, and 150 (this last passage is
representative of further passages up to 280).
Fig. 6. Expression of IL-17 and MMP12 in PER-VAS cells at passage 280.
Flow cytometry analysis of permeabilized cells using anti-MMP12 mAb (A) and anti-IL-17 mAb  (C), overlaid with FITC-labelled secondary Ab. Western blot analysis performed
under  reducing conditions using anti-MMP12 mAb  (B) and anti-IL-17 mAb  (D). Expression of actin has been used as a loading control. Jurkat and A20 cells have been used
as  positive controls respectively for MMP12 and IL-17. Recombinant human MMP12 (rhuMMP12) produced in COP5 murine cells was used as positive control for MMP12
detection.
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Table 3
Immunophenotype of PER-VAS cells from primary effusion cells to established cell line through 325 passages.
Passage number Flow cytometry (or ICC*) immunophenotype
rCD3 CD3 CD3 CD79a CD21 CD5 CD4 CD8 CD45 TCR TCR MHCII CD14 CD1a CD11c TLR3 IL-17 MMP12
Primary cells + * − * nd − * nd nd − * − * nd − * − * nd nd nd nd nd nd nd
P25  nd 60% nd nd − + − − + nd nd + − − − + nd nd
P50  nd 60% nd nd − + − − + nd nd + − nd nd + +low +low
P142: 4 months in liquid nitrogen
P145 nd 14% nd nd − + − − + nd nd + − nd nd + nd nd
P150  nd − nd nd − + − − + nd nd + − nd nd + nd nd
P199: 2 months in liquid nitrogen
P205 nd − − nd − + − − + nd nd + − nd nd + nd nd
P220  nd − − nd − + − − + nd nd + − − − + − +low
P260 nd − − nd − + − − + nd nd + − nd nd + + +
P280  nd − − nd − + − − + − * − * + − nd nd + + +
P280  : 1 year and an half in liquid nitrogen












































sP325: storage in liquid nitrogen
bbreviations: rCD3 = rabbit polyclonal anti-CD3; nd = not determined.
his cell line derived from an aggressive large granular T-cell lym-
homa with a CD3+ CD4- CD8- phenotype, resembling to human
arge granular lymphocytes (LGL) aggressive malignancies char-
cterized by (NK) or T-cell phenotype and frequent extra-nodal
nvolvement i.e. extra nodal NK/T cell lymphoma nasal type, aggres-
ive NK-cell leukemia and hepatosplenic T-cell lymphoma (Chan
t al., 1996; Turinelli et al., 2005). PER-VAS cells show a 16.5 h dou-
ling time which is a high proliferative rate when compared to
ther published canine lymphoma cell lines (Table 4). PER-VAS cells
ave a stable TCR gene rearrangement, and express CD5, CD45,
HC II surface antigens as well as cytoplasmic TLR3. Expression of
D3, CD56, IL-17, IFN and TNF mRNAs was conﬁrmed as late
s at passage 325. When compared to the other canine non B cell
ines published and still available (Table 4), phenotype differences
re observed with CL-1 which is CD5-, OSW which is CD5- and
hows oligoclonal TCR gene rearrangement, CLGL which is CD3+
nd TCR+, Ema  and Nody-1 which express surface CD3, UL-1
nd CLK which are MHCII-, and CLC which shows no TCR gene
earrangement.
As previously reported for CLC and CLK cell lines (Umeki et al.,
013), PER-VAS cells progressively lost CD3 staining with mon-
clonal antibody by ﬂow cytometry over time, while CD3 mRNA
xpression was detectable as late as at passage 325. The rapid loss
f normal T-cell antigens expression has already been reported
n human and canine T-cell leukemias (Avery and Avery, 2004;
ennings and Foon, 1997), and loss of markers is often observed
uring the transition from primary cells to cell lines. Nevertheless,
aking into account the positive result of polyclonal anti-CD3 by
mmunocytochemistry on primary effusion cells and PER-VAS cells
t passage 325 along with CD3 mRNA expression in PER-VAS cells,
e could conﬁrm intra-cytoplasmic CD3 expression in PER-VAS
ells, and consider that monoclonal anti-CD3 antibody recognizes
n epitope formed by interaction of the various chains of the com-
lete CD3 molecule, as it was proposed in human for the reactivity
f monoclonal Leu4 anti-CD3 in nasal T/NK cell lymphomas (Chan
t al., 1996).
Thus, it is noteworthy that the PER-VAS cells retained their
D5+/CD45+/MHCII+/TLR3+/CD4−/CD8−/CD21−/CD14− pheno-
ype as well as their intra-cytoplasmic expression of CD3 over the
 years period.
T-cell identity of PER-VAS cell line was witnessed by the mon-
clonal TCRγ gene rearrangement, which was revealed by PARR.
ntriguingly, protein expression of TCR (− and −) was unde-
ectable by immunocytochemistry both in primary effusion cells
nd in PER-VAS cell line.
Alternatively, CD56, IFN and TNF mRNA expression would
upport the belonging of PER-VAS cells to natural killer (NK) or nat-ural killer T (NKT) lineage. To date, NK cells are deﬁned as non-T,
non-B lymphoid cells, while in dogs, NK and T cells shared phe-
notypic characteristics such as CD3 and CD8 expression (Lin et al.,
2010; Otani et al., 2002; Shin et al., 2013). In human, CD56 is con-
sidered as a marker discriminating NK cells from other leukocytes
(Cooper et al., 2001). Due to the inability of the cross reactive
mAb  to recognize all forms of CD56 (Otani et al., 2002), canine
NK lineage was  assessed through either CD56 mRNA expression or
cytotoxic activity against canine thyroid adenocarcinoma cell line
(Bonkobara et al., 2005; Helfand et al., 1995; Shin et al., 2013). Inter-
estingly, we showed that PER-VAS cells expressed CD56, arguing
for a NK or NKT phenotype. In addition, a further characteriza-
tion of PER-VAS cells will be of interest with a cross reacting anti
bovine NCR1 antibody after the recent report of NCR1+ cells in
dogs that shared phenotypic characteristics with natural killer cells
(Grondahl-Rosado et al., 2015).
In human, TCR genes are in germ-line conﬁguration in NK-cells
while rearranged in NKT cells. The cytotoxic activity against tumor
cells was  reportedly mediated by NK cells rather than NKT cells
(Matsuo and Drexler, 2003; Voskens et al., 2010). Moreover, human
NKT cells can be broadly divided into CD4+ and CD4− subsets, with
CD4− NKT cells primarily producing the Th1 cytokines IFN and
TNF (Coquet et al., 2008). Thus, the rearrangement of TCR genes,
together with the expression of CD56, IFN and TNF mRNA sup-
port the belonging of PER-VAS cells to the NKT lineage.
Other studies suggested that CD56 may  not be a NK speciﬁc
marker. In human, CD56 expression has been reported in NKT-cell
lymphoma, in few cases of B-cell lymphomas (Gu and Ha, 2013;
Isobe et al., 2007), and in acute myeloid leukemia where it cor-
relates with proliferation and decreased apoptosis (Gattenloehner
et al., 2007). In dogs, a study indicated that CD56 mRNA was only
detected in a lymphoid leukemia case resembling human blastic
NK cell leukemia but not in malignant T and B cells collected for
controls (Bonkobara et al., 2007, 2005).
Cytoplasmic expression of IL-17 and MMP12 was  ﬁrst detected
by ﬂow cytometry in PER-VAS cells, and then analyzed by Western
blot. Given the predicted molecular weight of canine IL-17 (17 kDa),
the observed 26kDa band may  correspond to a N-glycosylated
form of IL-17, since recombinant human IL-17 migrated as two
bands of 15 and 22 kD on SDS-Page under reducing conditions, with
the higher molecular weight species representing N-glycosylated
form (Fossiez et al., 1996). In the same way, the anti-MMP12
mAb  revealed a band of 31 kDa for PER-VAS cells and 26 kDa
for recombinant human MMP12, in comparison with the 22 and
45 kDa predicted forms corresponding to the cleavage of the 54 kDa
MMP12 inactive enzyme (Shapiro et al., 1993). MMP12 is conserved
















Canine lymphoma/leukemia cell lines reported.
Cell line Derived from Diagnosis Flow cytometry (or ICCa) immunophenotype PARR PDT Publication or
published in
CD3 CD4 CD5 CD8 CD8 TCR TCR CD20 CD21 CD79a CD45 CD45RA MHCII TCR IgH
17-71 Lymph node Acute B cell
lymphoma
− nd nd nd nd − − nd − + + nd nd nd nd nd Steplewski et al.
(1987); Suter et al.
(2005)
GL-1 Peripheral blood B cell leukemia − 50% nd − nd nd nd nd − + + + − + − 27.3 h Nakaichi et al.
(1996); Rutgen
et al. (2010)





− nd nd nd nd nd nd nd − − + nd nd nd nd nd Suter et al. (2005)
CLGL-90 ni CLGL T cell
leukemia
+ nd nd nd + var + nd nd nd − nd nd nd nd nd nd Suter et al. (2005)
OSW Pl. ﬂuid T-cell lymphoma − − − − − − − + − − + − − oligo − 24 h Kisseberth et al.
(2007)
CLBL-1 Lymph node Diffuse large cell
lymphoma
− − − − nd nd − nd − + + + + − + 31 h Rutgen et al. (2010)
Ema  Pl. ﬂuid and ascite Gastrointestinal
lymphoma
+ − nd nd − − + nd − nd + + − + − 26.6 h Umeki et al. (2013)
CLC Pl. ﬂuid and ascite Gastrointestinal
lymphoma
− − nd nd − − − nd − nd + + + − − 14.5 h Umeki et al. (2013)
CLK Ascite Gastrointestinal
lymphoma
− − nd nd + − − nd − nd + + − + − 36.2 h Umeki et al. (2013)
Nody-1 Ascite Gastrointestinal
lymphoma
+ − nd nd − − − nd − nd + + + + − 21.5 h Umeki et al. (2013)
UL-1 Ascite Renal lymphoma − − nd nd + − − nd − nd + + − + − 20.9 h Umeki et al.
(2013); Yamazaki
et al. (2008)
PER-VAS Pericardic ﬂuid Aggressive T-cell
lymphoma
− − + − nd − − nd − − + nd + + − 16.5 h This study
Abbreviations: CLGL = chronic large granular lymphocytic; Pl. = Pleural; oligo = oligoclonal; var = variable; PDT = population doubling time; nd = not determined; ni = not indicated.
a ICC for CD20 and CD79a in (Kisseberth et al., 2007), and for CD79a in this study.




























































Fig. 7. mRNA expression pattern in PER-VAS cells.0 C. Bonnefont-Rebeix et al. / I
y the activation of other MMPs, leading to a cascade of proteolytic
rocesses (Gronski et al., 1997). MMP-12 was mainly found to be
xpressed in tumor-associated macrophages but also in tumoral
ells from aggressive B cell lymphomas (Ford et al., 2015) and nasal
K/T cell lymphomas (Kishibe et al., 2009). While MMPs  inhibitors
ay  be efﬁciently used in mice (Kondraganti et al., 2000; Yonemura
t al., 2001), several clinical trials in humans were not as efﬁcient
uggesting the need for better targeted inhibitors (Moore et al.,
003; Zucker et al., 2000). MMP-12, among other MMPs, was  shown
o be the primary protease responsible for proteolytic release of
ngiostatin from plasminogen, leading to the selective inhibition of
ndothelial cell proliferation, and thus retarding lung tumor growth
Houghton et al., 2006). While MMP-2 and -9 were able to induce
he degradation of plasminogen in vitro, they had a minor or no
ffect on the production of angiostatin in mice (Dong et al., 1997).
The IL-17 expression was detectable both at the transcript and
rotein level, at passages as late as 285 and 325. In human, IL-
7 is typically viewed as a product of Th17 CD4+ helper T cells
hich have a key role in autoimmune pathology, whereas NKT-17
ells are a subset of NKT cells family with CD4- NK1.1- pheno-
ype (Coquet et al., 2008). IL-17 is mainly a pro-inﬂammatory
ytokine that can induce secretion of chemokines, matrix metal-
oproteinases and pro-inﬂammatory cytokines from stromal cells,
eading to recruitment and activation of inﬂammatory cells. The
ole of IL-17 in carcinogenesis is complex, since IL-17 promotes
ngiogenesis and tumor growth in mice (Numasaki et al., 2003)
nd human (Matsuyama et al., 2011). IL-17 has also been shown
o inhibit tumorigenesis, in part by enhancing cytotoxic antitumor
esponses (Benchetrit et al., 2002; Murugaiyan and Saha, 2009). The
rst demonstration of IL-17 mRNA expression in human lymphoma
ells arose from cutaneous T-cell lymphomas (CTCL) (Ciree et al.,
004). IL-17 is also found in some cases of human anaplastic large
ell lymphoma (ALCL). Canine ALCL is not so well characterized.
Stable TLR3 expression in PER-VAS cells could be not surprising
ince lymphocytes are known to express all TLRs (Sandor and Buc,
005). In T cells, TLR2, TLR3, TLR5 and TLR9 act as co-stimulators
o the T-cell receptor and enhance proliferation and/or cytokine
roduction (Liu et al., 2006). NK cells were also found to express
LR3 which stimulation leads to TNF and IFN production and up-
egulation of cytolytic activity (Sivori et al., 2004). Among human
ymphoma subtypes, TLR expression is highly variable and repre-
ent potent therapeutic target (Smith et al., 2010). Sivori et al., 2007,
ound a correlation between the amount of TLR3 mRNA transcript,
xpressed in the NK cell clones, and their capability to respond to
oly (I:C) treatment.
In conclusion, PER-VAS is a novel canine lymphoma cell line
erived from an aggressive T-cell lymphoma with large granular
ell morphology, and presents a constant high proliferative growth
n culture over a 4 year period with freezing/thawing cycles. PER-
AS cells maintain a clonal TCR rearrangement, and present a
nique immunophenotype among canine cell-lines described up
o now, with mRNA expression of CD56, IL-17, IFN and TNF
etected as lately as at passage 325, suggesting a NKT lineage. Due
o its stability in culture and its rapid proliferation rate, PER-VAS
ell line will be of importance to decipher the molecular pathways
eading to lymphomas in dogs as well as a valuable tool to test new
herapeutic tools.
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